Compare BridgeBio Pharma Inc (BBIO) vs Consolidated Edison, Inc. (ED) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Consolidated Edison, Inc. — how do they compare? BridgeBio Pharma Inc trades at $84.09 (market cap $16.27B), while Consolidated Edison, Inc. trades at $111.89 (market cap $41.21B). The key difference: Consolidated Edison, Inc. is far larger — about 2.5× BridgeBio Pharma Inc's market cap, and Consolidated Edison, Inc. pays a 3.11% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | ED | |
|---|---|---|
Market Cap | $16.27B | $41.21B |
Sector | Health | Utilities |
52-Week High | $90.17 | $115.46 |
52-Week Low | $44.81 | $95.37 |
Enterprise Value | $17.82B | $68.24B |
Dividend Yield | — | 3.11% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Consolidated Edison, Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.
Read more on ED →
